Overview
deepmatter provides DigitalGlassware, a platform for capturing, structuring, and analyzing chemical reaction data to enhance reproducibility in pharmaceutical R&D. It integrates AI for predicting molecules, optimizing reactions, and accelerating drug discovery through partnerships like AstraZeneca and acquisitions such as ChemIntelligence. The technology supports automated synthesis, cloud-based data sharing, and AI-driven insights for preclinical development.
Frequently asked questions
- What is deepmatter's core technology for pharma R&D?
- DigitalGlassware captures real-time chemical reaction data including temperature, pressure, and catalysts, structuring it for AI analysis, reproducibility, and automated synthesis optimization.
- What partnerships demonstrate deepmatter's capabilities?
- deepmatter partners with AstraZeneca to improve compound synthesis productivity and reproducibility, and trialed its platform with Aurigene for custom drug discovery acceleration.
- How does deepmatter support regulatory compliance and data security?
- The platform operates in a secure end-to-end cloud environment, enabling structured data capture compliant with reproducibility standards for clinical trials and preclinical development.